Shandong Boan Biotechnology Co., Ltd
8
5
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
13%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Role: lead
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
Role: lead
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
Role: lead
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Role: lead
A Study of BA1202 in Patients With Advanced Solid Tumors
Role: lead
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
Role: lead
A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects
Role: collaborator
A Study to Evaluate the Denosumab in Healthy Adults
Role: collaborator
All 8 trials loaded